| Accession |
PRJCA023265 |
| Title |
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma |
| Relevance |
Medical |
| Data types |
Cytogenetic FISH testing
|
| Organisms |
Homo sapiens
|
| Description |
This is a Phase 1/2 first-in-human (FIH) study of the humanized immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) bispecific antibody, talquetamab, which was developed to evaluate the therapeutic potential of targeting GPRC5D for T cell redirection. The antibody binds to the CD3 receptor complex on T cells and to GPRC5D on plasma cells. It is hypothesized that by inducing enhanced T cell-mediated cytotoxicity through recruitment of CD3-expressing T cells to the GPRC5D-expressing cells, treatment with talquetamab will be an effective therapy for subjects with multiple myeloma. |
| Sample scope |
Multiisolate |
| Release date |
2024-01-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Janssen Research & Development, LLC
|
|
2021LP01360/2021LP01361
|
|
|
|
| Submitter |
gang
an (angang@ihcams.ac.cn)
|
| Organization |
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences |
| Submission date |
2024-01-26 |
